Benzinga | Jan 7, 2021 07:09AM EST

CareDx And IDbyDNA Announce Exclusive Partnership Focused On 'the development of metagenomic infectious disease testing specific to transplant patients'; Companies will Develop AlloID Tailored Infectious Disease Testing Solution

SOUTH SAN FRANCISCO, Calif. and SALT LAKE CITY, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Today, CareDx, the leading partner in transplant care, and IDbyDNA, the company revolutionizing the use of precision metagenomics, announced an exclusive partnership focused on the development of metagenomic infectious disease testing specific to transplant patients. The companies will develop and commercialize AlloID, a tailored infectious disease testing solution that identifies more than 100 pathogens and drug resistance in viruses and bacteria, specific to organ transplant donors and recipients.